AVENIO Tumor Tissue Analysis Kits

AVENIO Tumor Tissue Analysis Kits are a portfolio of NGS assays that provide in-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance & monitoring for clinical research. Through an optimized, end-to-end workflow, the kits offer a versatile solution to evaluate DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples.

• Matched tissue and liquid biopsy (ctDNA) panels (same genes, gene regions and hybrid-capture workflow) for AVENIO Targeted, Expanded, and Surveillance Kits V2 to facilitate concordance analysis
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA research workflow¹
• A streamlined, end-to-end research workflow from extraction to analysis and reporting in 5 days
• An integrated solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high-performance NGS oncology research

• Matched tissue and liquid biopsy (ctDNA) panels (same genes, gene regions and hybrid-capture workflow) for AVENIO Targeted, Expanded, and Surveillance Kits V2 to facilitate concordance analysis
• Flexibility to switch between tissue and plasma to support a variety of research applications

• Built on the combined expertise of Roche and Foundation Medicine, Inc.^2,3
• Utilizes fast and convenient next-generation sequencing workflows with xylene-free reagents³
• Unlocks meaningful genomic insights using a comprehensive 335-gene panel aligned with FoundationOne® CDx panel design^2,3
• Covers all four classes of genomic variants - SNVs, InDels, CNAs, and REs and complex signatures - TMB, MSI, gLOH and HRD^2,3
• Incorporates the new pan-cancer HRDsignature developed by Foundation Medicine using over 100 copy number features using a proprietary machine learning algorithm trained on over 500,000 high-quality genomic profiles^3,4